文献速递脊柱关节炎

赛妥珠单抗聚乙二醇治疗中轴型脊柱关节炎减轻脂肪病变发展:一项3期研究4年事后MRI结果

Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

RAPID-axSpA 4年3期随机试验的事后分析纳入136例中轴型脊柱关节炎患者,评估赛妥珠单抗聚乙二醇(CZP)对脊柱椎缘脂肪病变(FL)的影响。安慰剂随机后转用CZP组(PBO-randomized/CZP)较CZP随机组在48、96、204周时FL相对基线的OR更高。基线存在炎症的椎缘FL增加多于无炎症者;12周内炎症消退的椎缘后续FL患病率更低。

要点

  • PBO-randomized/CZP组较CZP随机组FL相对基线OR在48、96、204周均更高
  • 基线有炎症的椎缘204周FL的OR为4.84,无炎症者为1.15
  • 12周内炎症消退的椎缘在48、96、204周FL患病率低于未消退者

核心结论

  • 在4年评估期内,早期且持续抑制炎症可减轻中轴型脊柱关节炎研究参与者脊柱长期FL发展的风险。

研究设计与样本

  • RAPID-axSpA(NCT01087762)为4年3期随机试验的事后分析,基线随机分配至赛妥珠单抗聚乙二醇(CZP;第0/2/4周400 mg负荷剂量,之后200/400 mg每2/4周)或安慰剂(PBO),PBO随机参与者在第16/24周转用CZP(记为PBO-randomized/CZP)。
  • 脊柱MRI于第0、12、48、96和204周采集。
  • 共136例参与者(CZP:89例,PBO-randomized/CZP:47例)有基线和至少一次基线后MRI。

主要发现

  • FL相对基线的OR(95%CI)在PBO-randomized/CZP组 vs CZP随机组分别为:第48周3.35(2.16-5.19) vs 1.45(1.07-1.97),第96周2.62(1.77-3.88) vs 1.84(1.36-2.48),第204周2.55(1.59-4.06) vs 1.71(1.23-2.37)。
  • 204周内,基线有炎症的椎缘FL增加多于无炎症者:第204周OR分别为4.84(2.56-9.18)与1.15(0.78-1.71)。
  • 12周内炎症消退的椎缘在第48、96和204周FL患病率低于炎症未消退的椎缘。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Fat lesions (FLs) on MRI T1 sequences are considered to be early indicators of structural spinal progression in axial spondyloarthritis (axSpA) patients. In this post-hoc analysis from RAPID-axSpA, we assess whether tumour necrosis factor inhibitor (TNFi) treatment over 4 years impacts FLs in spinal vertebral edges (VEs) of patients with axSpA. METHODS: In RAPID-axSpA (NCT01087762), a 4-year, phase 3 randomized trial, participants were randomized to certolizumab pegol (CZP; 400 mg loading dose at Weeks 0/2/4 then 200/400 mg every 2/4 weeks) or placebo (PBO) at baseline; PBO-randomized participants switched to CZP at Week 16/24 (denoted PBO-randomized/CZP). Spinal MRI scans were taken at Weeks 0, 12, 48, 96 and 204. Changes in proportions of VEs with FLs are reported as odds ratios (ORs) between time points. RESULTS: Overall, 136 participants (CZP: 89, PBO-randomized/CZP: 47) had a baseline and ≥1 post-baseline MRI. The OR (95% confidence interval) vs baseline of FLs was higher in PBO-randomized/CZP vs CZP-randomized participants at Weeks 48 [3.35 (2.16-5.19) vs 1.45 (1.07-1.97)], 96 [2.62 (1.77-3.88) vs 1.84 (1.36-2.48)] and 204 [2.55 (1.59-4.06) vs 1.71 (1.23-2.37)]. Across 204 weeks, FLs increased more in VEs with baseline inflammation [Week 204 OR: 4.84 (2.56-9.18)] than those without [OR: 1.15 (0.78-1.71)]. VEs in which inflammation was resolved by Week 12 had lower FL prevalence at Weeks 48, 96 and 204 compared with VEs with unresolved inflammation. CONCLUSIONS: Early and sustained suppression of inflammation mitigates the risk of long-term FL development in the spine in study participants with axSpA evaluated over 4 years. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT01087762.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Baraliakos X, Kruse S, Auteri SE, et al. Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study. Rheumatology (Oxford). 2022. PMID: 34791107. doi:10.1093/rheumatology/keab841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。